Treatment strategies for clear cell renal cell carcinoma: Past, present and future.

Autor:	Yang J; Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China., Wang K; Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China.; Department of Pathology, School of Basic Medical Science, Central South University, Changsha, Hunan, China.; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China., Yang Z; Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2023 Mar 21; Vol. 13, pp. 1133832. Date of Electronic Publication: 2023 Mar 21 (Print Publication: 2023).
DOI:	10.3389/fonc.2023.1133832
Abstrakt:	Clear cell renal cell carcinoma (ccRCC) is the most prevalent histological subtype of kidney cancer, which is prone to metastasis, recurrence, and resistance to radiotherapy and chemotherapy. The burden it places on human health due to its refractory nature and rising incidence rate is substantial. Researchers have recently determined the ccRCC risk factors and optimized the clinical therapy based on the disease's underlying molecular mechanisms. In this paper, we review the established clinical therapies and novel potential therapeutic approaches for ccRCC, and we support the importance of investigating novel therapeutic options in the context of combining established therapies as a research hotspot, with the goal of providing diversified therapeutic options that promise to address the issue of drug resistance, with a view to the early realization of precision medicine and individualized treatment. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Yang, Wang and Yang.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu